Quantcast

Latest Warfarin Stories

2014-09-10 23:01:31

The Firm is evaluating Xarelto lawsuits on behalf of individuals who suffered life-threatening internal bleeding, stroke, deep vein thrombosis, pulmonary embolism, or other serious injuries allegedly due to their use of the blood-thinning medication. New York, New York (PRWEB) September 10, 2014 A California woman has filed a new Xarelto lawsuit (http://www.xareltolawsuitcenter.com) that alleges uncontrollable hemorrhaging caused by the blood thinner nearly ended her life, Bernstein...

2014-09-04 23:01:58

The results of a recently-concluded study purport to show that Xarelto (rivaroxaban) is as safe as warfarin for patients atrial fibrillation patients awaiting elective cardioversion, even though four persons included in the study died. Rockville Centre, NY (PRWEB) September 04, 2014 According to an article published on September 2 at medpagetoday.com, atrial fibrillation patients awaiting elective cardioversion who had their oral anticoagulant switched from warfarin to Xarelto “were...

2014-09-02 23:01:40

The Firm is evaluating Xarelto lawsuits on behalf of patients who suffered uncontrollable internal bleeding, stroke, deep vein thrombosis, pulmonary embolism, or death, allegedly due to their use of the blood thinner. New York, NY (PRWEB) September 02, 2014 The use of Xarelto (known generically as rivaroxaban) and other new blood thinners is growing at a rapid pace, even as Xarelto lawsuits (http://www.xareltolawsuitcenter.com) continue to mount in courts around the U.S., Bernstein...

2014-09-02 08:31:44

Results presented during ESC Congress 2014 Clinical Trial Update Hot Line session BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation (NVAF). The analysis also compared rates of major bleeding and...

2014-09-02 08:30:31

Patients at higher risk of kidney problems due to existing diabetes were also evaluated for the effects of warfarin on kidney function RIDGEFIELD, Conn., Sept. 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial assessing renal function change in patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa® (dabigatran etexilate mesylate) compared to warfarin. The...

2014-09-02 04:21:13

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today results from the X-VeRT trial, demonstrating once-daily XARELTO(®) (rivaroxaban) may be an alternative to vitamin K antagonists (VKA) in treating and reducing the risk of blood clots in non-valvular atrial...

2014-08-28 08:27:34

Company poised to enter final pivotal trial for novel oral anti-coagulant MENLO PARK, Calif., Aug. 28, 2014 /PRNewswire/ -- Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The Series A round was co-led by AshHill Biomedical Investments and Hercules Bioventures with participation from investors that included...

2014-08-27 23:12:45

A study released August 1 highlights the challenges related to managing anticoagulant–associated intracerebral hemorrhage (AAICH). Washington, D.C. (PRWEB) August 27, 2014 A recently published study by the Journal of Neurosurgery discusses the importance of time in correcting coagulopathy to prevent permanent injury or death. The study focuses on a variety of anticoagulants and examines medical conditions alleged to be caused by these drugs. According to the research, although...

Aspirin May Reduce The Risk Of Blood Clots Reoccurring
2014-08-27 03:05:36

American Heart Association Aspirin may be a promising alternative for those who can’t take long-term anticoagulant drugs that prevent clots from reoccurring in the veins, according to new research in the American Heart Association journal Circulation. In a combined analysis of two similar independent studies, 1,224 patients who received 100 mg of aspirin a day to treat blood clots were monitored for at least two years. In the International Collaboration of Aspirin Trials for...

2014-08-25 08:27:37

-- Results from X-VeRT, the first prospective exploratory study of a Factor Xa inhibitor in patients with atrial fibrillation undergoing cardioversion, will be presented during an ESC Congress 2014 Hot Line Session RARITAN, N.J., Aug. 25, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that results from the Phase 3b exploratory X-VeRT study, investigating the oral Factor Xa inhibitor XARELTO(®) (rivaroxaban) in patients with non-valvular atrial...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related